Latest statistics and disclosures from VR Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CNST, OLMA, TRIL, KNTE, ATHA, and represent 53.74% of VR Adviser's stock portfolio.
- Added to shares of these 10 stocks: OLMA (+$74M), KNTE (+$59M), MRNS (+$32M), VTGN (+$18M), ACRS (+$13M), COGT (+$12M), ALGS (+$11M), SNDX (+$11M), GRTX (+$8.9M), SBTX (+$7.0M).
- Started 11 new stock positions in COGT, VTGN, KNTE, SBTX, ACRS, MRNS, ALGS, OLMA, VRDN, FPRX. BCAB.
- Reduced shares in these 10 stocks: TRIL (-$47M), Humanigen (-$25M), SURF (-$23M), CRDF (-$18M), IMV (-$18M), Marinus Pharmaceuticals (-$15M), ALXO (-$11M), Unum Therapeutics Ord (-$10M), Fs Dev Corp (-$5.6M), MTCR.
- Sold out of its positions in ALXO, CRDF, Fs Dev Corp, Humanigen, IMV, Marinus Pharmaceuticals, MDNA, Unum Therapeutics Ord.
- VR Adviser was a net buyer of stock by $83M.
- VR Adviser has $680M in assets under management (AUM), dropping by 33.06%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of dataDownload as csv Download as Excel
Portfolio Holdings for VR Adviser
Companies in the VR Adviser portfolio as of the December 2020 quarterly 13F filing
|Company (Ticker)||Portfolio Weight||Valued At||Change in Shares||Share Count||Share Price|
|Constellation Pharmceticls I (CNST)||17.0||$116M||4.0M||28.80|
|Olema Pharmaceuticals (OLMA)||10.9||$74M||NEW||1.5M||48.08|
|Trillium Therapeutics, Inc. Cmn (TRIL)||8.7||$59M||-43%||4.0M||14.71|
|Kinnate Biopharma (KNTE)||8.6||$59M||NEW||1.5M||39.78|
|Athira Pharma (ATHA)||8.5||$58M||+11%||1.7M||34.25|
|Keros Therapeutics (KROS)||7.0||$47M||672k||70.54|
|Marinus Pharmaceuticals (MRNS)||4.6||$32M||NEW||2.6M||12.20|
|Syndax Pharmaceuticals (SNDX)||3.6||$25M||+78%||1.1M||22.24|
|Relmada Therapeutics (RLMD)||3.2||$21M||668k||32.07|
|Kura Oncology (KURA)||2.8||$19M||575k||32.66|
|Vistagen Therapeutics (VTGN)||2.7||$18M||NEW||9.4M||1.94|
|Celldex Therapeutics (CLDX)||2.1||$14M||800k||17.52|
|Surface Oncology (SURF)||2.0||$13M||-62%||1.4M||9.24|
Setup an alert
VR Adviser will file the next quarterly 13-HR in about 1 months. Would you like to be notified?
|Aclaris Therapeutics (ACRS)||1.9||$13M||NEW||2.0M||6.47|
|Cogent Biosciences (COGT)||1.8||$12M||NEW||1.1M||11.23|
|Aligos Therapeutics (ALGS)||1.6||$11M||NEW||405k||27.65|
|Galera Therapeutics (GRTX)||1.4||$9.4M||+1676%||918k||10.23|
|Silverback Therapeutics (SBTX)||1.0||$7.0M||NEW||150k||46.34|
|Bctg Acquisition Corp (BCTG)||0.8||$5.7M||500k||11.44|
|Metacrine Ord (MTCR)||0.8||$5.5M||-39%||694k||7.86|
|Five Prime Therapeutics (FPRX)||0.6||$4.2M||NEW||245k||17.01|
|Taysha Gene Therapies Com Shs (TSHA)||0.4||$2.9M||108k||26.54|
|Miragen Therapeutics (VRDN)||0.0||$321k||NEW||20k||16.47|